The smaller variety of anticipated doses, which seemed to be the results of a scheduling hiccup, reignited tensions between the federal authorities and Pfizer over vaccine provide.

Officials in a number of states mentioned that they had been caught off guard on Wednesday once they discovered that subsequent week’s cargo of the Pfizer-BioNTech vaccine would comprise fewer doses than the primary week.

In Oregon, state well-being officers mentioned they had been advised they had been solely scheduled to get 25,350 doses of the vaccine subsequent week, considerably lower than the 40,950 doses that the state acquired this week. Iowa’s public well-being division issued an identical launch, saying they had been advised “they will not receive the volume of vaccine initially anticipated,” and that their cargo could be as a lot as 30 p.c lower than what they acquired this week.

Officials with Operation Warp Speed, the federal effort to distribute a Covid-19 vaccine to the general public, additionally mentioned Wednesday that they’d allotted solely 2 million doses for subsequent week’s cargo, lower than the two.9 million that had been delivered this week. The officers mentioned they anticipate to ship 5.9 million doses subsequent week of a vaccine developed by Moderna, which is anticipated to be licensed by the Food and Drug Administration on Friday.

The transfer despatched some states scrambling to regulate their plans and raised questions on whether or not federal officers will be capable to meet their objective of administering an preliminary shot of the two-dose Pfizer and Moderna vaccines to twenty million individuals by January 1, simply two weeks away.

The smaller cargo seemed to be the results of a scheduling hiccup created when federal officers, responding to a request by states, determined to allocate subsequent week’s doses this Tuesday as a substitute of on Friday, as they’d deliberate. States had requested federal officers for extra time to plan their allotments earlier than deliveries start on Monday, however doing so meant that the federal authorities couldn’t embody in that transport estimate extra vaccine batches that had been launched after Tuesday, in response to a senior administration official.

The batches of vaccine that weren’t included in subsequent week’s allocation might be included within the cargo the next week, the official mentioned.

The official, who agreed to talk on situation of anonymity as a result of he was not licensed to debate the shipments, mentioned it was unclear whether or not future weekly shipments would enhance as a result of the federal government didn’t have a very good view into Pfizer’s manufacturing course of. Unlike different corporations that took federal funding for growth and manufacturing of their Covid vaccines, Pfizer signed an advance buy settlement by which it’s only paid if the vaccines are delivered. The official additionally mentioned that the corporate’s manufacturing estimates had fallen in current weeks.

Pfizer mentioned in a press release on Wednesday that the corporate “is not having any production issues with our Covid-19 vaccine, and no shipments containing the vaccine are on hold or delayed.” The firm additionally mentioned, “We have millions more doses sitting in our warehouse but, as of now, we have not received any shipment instructions for additional doses.”

The firm additionally mentioned it had shared with the federal authorities “every aspect” of its manufacturing and distribution course of. “They have visited our facilities, walked the production lines and been updated on our production planning as information has become available,” the assertion mentioned.

This fall, Pfizer halved preliminary estimates that it might make 100 million doses by the top of the 12 months after operating into manufacturing delays brought on by difficulties finding gear and uncooked supplies, in addition to needing extra doses for an enlargement of its medical trial. In November, the chief govt, Dr. Albert Bourla, mentioned about 25 million doses would go to the United States. On Wednesday, a Pfizer spokeswoman mentioned that the corporate would be capable to distribute 20 million doses in December within the United States.

The controversy over short-term deliveries is enjoying out towards a backdrop of tense negotiations between Pfizer and the federal authorities over a brand new contract for tens of hundreds of thousands of extra doses within the first half of subsequent 12 months. The two sides hope to succeed in an settlement by Christmas, however Pfizer has mentioned it wants the federal authorities to make use of its authority to pressure suppliers to prioritize its orders — a request that one individual aware of the negotiations mentioned has been pending for months.

The authorities needs Pfizer to promote it 100 million extra doses — sufficient to cowl a further 50 million Americans — between the beginning of April and the top of June. Pfizer has mentioned that it might solely present about 70 million doses then as a result of different international locations have already purchased its remaining inventory.

The subject is particularly fraught as a result of, in response to individuals aware of Pfizer’s model of occasions, the agency repeatedly requested the Trump administration to pre-order extra doses starting in late summer time however the administration did not act till Nov. 25 — greater than two weeks after Pfizer introduced the outcomes from medical trials exhibiting its vaccine was protected and greater than 95 p.c efficient.

Now either side are scrambling to determine how Pfizer can increase its manufacturing to double the variety of doses the agency can ship for Americans within the first half of the subsequent 12 months. So far, the Trump administration has solely locked in a complete of 300 million doses from Pfizer and Moderna. Because each vaccines require two doses, excluding the kids and youngsters for whom no vaccine is but accepted, that also leaves greater than 100 million Americans uncovered.

Alex M. Azar, the secretary of Health and Human Services, alluded to the friction with Pfizer in an interview on Thursday morning with CNBC, saying “I do wish we would just stop talking about this Pfizer thing.” He added that the federal authorities was prepared to assist Pfizer in manufacture extra “if they are willing to take our help.”

Abby Goodnough contributed reporting.